China NMPA Legal Agent Services

The NMPA Legal Agent is the local authorized representative for any MedTech and IVD manufacturer located outside China. The NMPA* Legal Agent must be a Chinese entity. Just as for submissions in Europe and US, all dossier or product approval submissions to Chinese authorities must be made by the China Agent.

*NMPA stands for the National Medical Products Administration, which is China’s regulatory authority responsible for medical devices.

The official name of the authorized representative role is expected to change from Legal Agent to Domestic Responsible Agent. This was proposed in the draft Medical Device Law which is set to replace the current regulation Order 739. The draft was released in draft format for public comment on August 26, 2024.

Selecting the most appropriate form of Chinese local representation is an important early step in the filing or registration process for your medical device, together with choosing the right agent to ensure compliance and proper representation.

Cisema - your China in country agent
China agent

There are 3 broad categories of local representative available to overseas companies:

1

Choosing a Local Distributor

2

Setting Up a Chinese Subsidiary
or Legal Entity

3

Appointing an Independent 
Service Provider

Cisema Acts as an Independent Service Provider of Services for a Growing Number of Companies

Below we set out the advantages and setbacks of each option:

Distributor

Distributor may offer to cover upfront investment required to register in return for lower transfer price
Possible IP violation as the Distributor has access to sensitive information as part of the registration process
Distributor retains control of registration certificates which can impact imports, change notifications and renewals
No other Distributor can be added without their approval; it can also be difficult to replace Distributor

Own Subsidiary

Retain full control of certificates and therefore flexibility in choosing as many channel partners as required
Requires an established and well-functioning Post-Market Surveillance system in China to conform with NMPA requirements
Considerable investment required to set up a company, find and hire qualified and experienced regulatory experts

Distributor

Qualified and experienced regulatory and quality experts available immediately to register your product and undertake Post-Market Surveillance
Retain full flexibility in choosing or replacing channel partners as required
Retain full control of certificates
Annual representation fees/costs

Role of a China Agent

A China Agent plays a crucial role in applying for medical device and IVD filings and registrations. Acting as the official representative for the foreign companies, the agent is responsible for submitting applications, communicating with the NMPA, and ensuring that all regulatory requirements are met.

This role demands a deep understanding of the Chinese regulatory framework and mandates that the agent be a Chinese legal entity.

By navigating the complexities of the regulatory landscape, the in country representative ensures that the foreign manufacturer’s products comply with local laws, facilitating a smoother entry into the Chinese market.

Role of a China Agent

Responsibilities of an NMPA Legal Agent

They play a critical role throughout the entire product registration process and product lifecycle in China. Acting on behalf of the overseas manufacturer, the legal agent ensures full compliance with relevant regulations issued by the NMPA and the State Council. This includes submitting and maintaining the registration application, managing communications with authorities, and holding a valid business license in China.

The agent is also responsible for adverse event reporting and monitoring, ensuring timely updates and transparency in line with Chinese requirements. They help implement product traceability and an effective recall system to maintain product quality and safeguard public health.

In addition, the legal agent must keep the original NMPA certificate, inform the authorities of any change in the legal manufacturer or appointment of a new agent, and support ongoing regulatory compliance. Their support enables the overseas manufacturer and their Chinese distributor or sales agents to focus on business growth while maintaining regulatory alignment in the country.

Can I Change My Agent?

Yes, changing your Chinese Agent is possible. Manufacturers often consider this when dissatisfied with their current agent, especially if the agent is also their distributor. In such cases, appointing an independent agent like Cisema can provide greater transparency and control.

The process typically takes around seven weeks and requires a copy of the NMPA registration certificate and the Product Technical Requirements (PTR). Obtaining these documents from distributors who handled the original application can sometimes be challenging, but we’re here to help you overcome this hurdle—reach out to us if you're facing this situation.

Can I Become My Own Agent in the Future?

Yes, this is quite common for companies which shift to manufacturing in China. A foreign manufacturer that sets up an organization in China can, in principle, act as their own agent. This local company must satisfy the NMPA's regulatory requirements and is legally responsible for compliance during the entire product life cycle - which includes product registration, post market surveillance, and communication with authorities.

Cisema can remain contracted to assist with communications and post-market surveillance, while some businesses look to adopt this responsibility themselves once local operations are properly set up. Taking on these operational duties in-house allows for greater oversight, but it does mean hiring resources to understand the regulatory framework within China and its changes.

If you’re planning to manufacture in China and wish to eventually act as your own Legal Agent, we can assist in facilitating a seamless transition—feel free to reach out for guidance.

Adverse events

Our China NMPA Legal Agent Services

As your local authorized representative in China, we are your single point of contact for all NMPA matters. As we are independent of any distributor, we ensure that you maintain control of your product registrations and retain an unconstrained choice of your market access partner(s), giving you full flexibility to adapt as necessary to changes in the market.

Our services include:

Prepare, Submit & Follow Up Applications to the NMPA:

NMPA Online Account
Filings & registrations
Change & product extension
Change of local authorized representative
Class II & III renewals
Advertisement approval
Medical Insurance Code
UDI

Regulatory & Quality Assurance Support for “Made in China” Certification Including:

Acting as your MAH
QMS gap analysis & adaptation
CMO pre-audit and assistance
Post-Market Surveillance & auditing of CMO 

Other Services Include:

Provide regulatory & standards updates and news related to your filings & registrations 
Review of Chinese names, labels & IFUs 
Cooperate with regulatory authorities for market supervision and inspection activities. 
Customs clearance & tender bidding support 

Request a Proposal from our Life Sciences Team about Appointing us or Changing your Agent to Cisema

Let Cisema help turn your plans into reality.

Request Proposal

Latest Insights from Cisema

View More

China NMPA Medical Device Registration Timeline Calculator

Use our interactive calculator to estimate your China NMPA medical device registration timeline, key milestones, and approval window.

November 17, 2026
China NMPA Medical Device Registration Timeline Calculator

Do You Need a China Medical Device Clinical Trial? [Quick Check]

Answer a few quick questions and get a preliminary assessment of whether your medical device requires a China clinical trial for NMPA registration.

November 17, 2026
Do You Need a China Medical Device Clinical Trial? [Quick Check]

How the Indonesia Halal Certification Process Works (SIHALAL): A Guide to the SHLN & Regular Certification Pathways

Learn how the BPJPH process works for foreign certificates (SHLN) and regular SIHALAL applications.

November 3, 2026
How the Indonesia Halal Certification Process Works (SIHALAL): A Guide to the SHLN & Regular Certification Pathways

5-Step Guide to the GBA Connect Scheme for Medical Manufacturers

Discover how overseas medical companies can access China early via the GBA Connect Pathway, with a 5-step process and hospital coordination tips.

November 2, 2026
5-Step Guide to the GBA Connect Scheme for Medical Manufacturers

Key Requirements for Indonesia Halal Medical Devices: What Manufacturers & Importers Need to Know

Learn which products are covered by Indonesia's halal framework, the labeling and manufacturing obligations, and phased compliance timelines.

November 2, 2026
Key Requirements for Indonesia Halal Medical Devices: What Manufacturers & Importers Need to Know
A healthcare worker in a white coat checks a seated patient’s blood pressure while another medical staff member in green scrubs stands nearby holding a clipboard in a bright clinic setting.

Is a Foreign Halal Certificate Valid in Indonesia? Requirements Explained

Understand Indonesia’s foreign halal certificate requirements, including covered categories and BPJPH registration routes.

November 2, 2026
Is a Foreign Halal Certificate Valid in Indonesia? Requirements Explained
Previous
Previous

Explore Related Services

Whether you’re just starting out or are a blue-chip, access our wide range of services and solutions to help your business thrive.

China Medical Device Registration

We guide you through every step of the China medical device registration and filing process. We take care of compliance with NMPA requirements, advising you on the optimal market entry pathway, and helping you through the whole process.

Learn more

NMPA Type Testing

We provide end-to-end support for China type testing in NMPA-accredited laboratories. Our experienced test engineers offer on-site supervision to guarantee accurate and reliable results.

Learn more

China Clinical Trials

You may be required to provide supplementary clinical data on Chinese patients or conduct a full clinical trial in China.Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.

Learn more

NMPA Clinical Evaluation Report

CERs can avoid the need for a China clinical trial in some instances. Our experts can advise and prepare NMPA compliant CERs.

Learn more

Drug Device Combination Products

We assist with the classification, registration, and compliance of combination products in China, whether drug or device led.

Learn more

China Medical Device Quality Compliance

We help you achieve and ensure ongoing compliance with Chinese requirements.Our experts prepare and assist you for official NMPA inspections.

Learn more

Medical Device PMS & Vigilance

The NMPA is placing greater focus on Post-Market Surveillance (PMS) such as more in-market sampling inspections and regular standard changes.

Learn more

Regulatory Outsourcing

If you are seeking specific specialist expertise or have ongoing resource-intensive needs, we have a variety of solutions to meet your needs.

Learn more

Latest Regulatory News

View More

China Issues GMP Inspection Guidelines for Sterile, Implant, IVD, Denture and Standalone Software Devices

China has introduced GMP inspection guidelines for sterile, implantable, IVD, custom-made denture and standalone software medical devices.

November 16, 2026
China Issues GMP Inspection Guidelines for Sterile, Implant, IVD, Denture and Standalone Software Devices
Two Chinese laboratory professionals check a benchtop blood analyzer as one loads a rack of capped sample tubes.

India Clarifies How Medical Device Software, and AI-Enabled Tools Are Regulated

India’s CDSCO releases final medical device software guidance under MDR 2017, outlining licensing routes, software risk classes, and cybersecurity standards.

November 16, 2026
India Clarifies How Medical Device Software, and AI-Enabled Tools Are Regulated
Two Indian clinicians review a chest X-ray on a tablet, where diagnostic software has flagged an area in one lung.

Singapore Updates GN-15 Medical Device Registration Guidance

Singapore’s HSA has revised GN-15 medical device registration guidance, updating submission templates, SaMD requirements and post-market expectations.

November 12, 2026
Singapore Updates GN-15 Medical Device Registration Guidance

Indonesia Extends Mandatory Halal Certification Deadlines

Indonesia extends halal certification deadlines for medicines, medical devices, cosmetics, and other regulated products, giving additional time to meet compliance requirements.

November 3, 2026
Indonesia Extends Mandatory Halal Certification Deadlines

China Issues Battery Registration Guidance for Active Implantable Medical Devices

See how China’s new battery registration guidance affects technical documentation, supplier coordination, and NMPA review of active implantable medical devices.

November 2, 2026
China Issues Battery Registration Guidance for Active Implantable Medical Devices

China Issues Clinical Trial Guidance for Implantable Brain-Computer Interface Systems

China's CMDE guidance defines clinical trial and registration considerations for implantable BCI devices, including patient selection, endpoints, and post-market follow-up.

November 2, 2026
China Issues Clinical Trial Guidance for Implantable Brain-Computer Interface Systems
Previous
Previous

Ready to Navigate Complexity & Achieve Success in China & Asia Pacific?

Let Cisema help turn your plans into reality.

Talk to an Expert